共 83 条
[1]
Abet V., Filace F., Recio J., Alvarez-Builla J., Burgos C., Prodrug approach: an overview of recent cases, Eur. J. Med. Chem., 127, pp. 810-827, (2017)
[2]
Buchwald P., Soft drugs: design principles, success stories, and future perspectives, Expet Opin. Drug Metabol. Toxicol., 16, pp. 645-650, (2020)
[3]
Beaumont K., Webster R., Gardner I., Dack K., Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist, Curr. Drug Metabol., 4, pp. 461-485, (2003)
[4]
Lee J.B., Zgair A., Malec J., Kim T.H., Kim M.G., Ali J., Qin C., Feng W., Chiang M., Gao X., Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system, J. Contr. Release, 286, pp. 10-19, (2018)
[5]
Larsen E.M., Johnson R.J., Microbial esterases and ester prodrugs: an unlikely marriage for combating antibiotic resistance, Drug Dev. Res., 80, pp. 33-47, (2019)
[6]
Casey Laizure S., Herring V., Hu Z., Witbrodt K., Parker R.B., The role of human carboxylesterases in drug metabolism: have we overlooked their importance?, Pharmacotherapy, The Journal of Human Pharmacology and Drug Therapy, 33, pp. 210-222, (2013)
[7]
Davies R.O., Gomez H.J., Irvin J.D., Walker J.F., An overview of the clinical pharmacology of enalapril, Br. J. Clin. Pharmacol., 18, pp. 215S-229S, (1984)
[8]
Roholt K., Nielsen B., Kristensen E., Clinical pharmacology of pivampicillin, Antimicrob. Agents Chemother., 6, pp. 563-571, (1974)
[9]
Ward P., Small I., Smith J., Suter P., Dutkowski R., Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic, J. Antimicrob. Chemother., 55, pp. i5-i21, (2005)
[10]
Forman S.A., Warner D.S., Clinical and molecular pharmacology of etomidate, The Journal of the American Society of Anesthesiologists, 114, pp. 695-707, (2011)